ES2038658T3 - Una formulacion farmaceutica conteniendo indometacina. - Google Patents

Una formulacion farmaceutica conteniendo indometacina.

Info

Publication number
ES2038658T3
ES2038658T3 ES198787302426T ES87302426T ES2038658T3 ES 2038658 T3 ES2038658 T3 ES 2038658T3 ES 198787302426 T ES198787302426 T ES 198787302426T ES 87302426 T ES87302426 T ES 87302426T ES 2038658 T3 ES2038658 T3 ES 2038658T3
Authority
ES
Spain
Prior art keywords
indometacine
pharmaceutical formulation
formulation containing
carboxylic acid
metabolisable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787302426T
Other languages
English (en)
Inventor
Kim Drummond Rainsford
Michael Wellesley Whitehouse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2038658T3 publication Critical patent/ES2038658T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

UNA PREPARACION FARMACEUTICA QUE COMPRENDE INDOMETACINA COMO FARMACO DE ACTIVIDAD ANTINFLAMATORIA Y UN ACIDO CARBOXILICO METABOLIZABLE Y UNA SAL DE UN ACIDO CARBOXILICO METABOLICO Y UN CARBOHIDRATO METABOLIZABLE PARA PROTEGER AL ESTOMAGO Y AL TRACTO INTESTINAL DEL DAÑO QUE PUEDE CAUSAR EL FARMACO.
ES198787302426T 1986-03-27 1987-03-20 Una formulacion farmaceutica conteniendo indometacina. Expired - Lifetime ES2038658T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868607662A GB8607662D0 (en) 1986-03-27 1986-03-27 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
ES2038658T3 true ES2038658T3 (es) 1993-08-01

Family

ID=10595349

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787302426T Expired - Lifetime ES2038658T3 (es) 1986-03-27 1987-03-20 Una formulacion farmaceutica conteniendo indometacina.

Country Status (17)

Country Link
US (1) US4885279A (es)
EP (1) EP0239332B1 (es)
JP (1) JPS6322017A (es)
AT (1) ATE60993T1 (es)
AU (1) AU593084B2 (es)
CA (1) CA1285488C (es)
DE (1) DE3768110D1 (es)
DK (1) DK154887A (es)
ES (1) ES2038658T3 (es)
GB (1) GB8607662D0 (es)
GR (1) GR3001520T3 (es)
IE (1) IE59636B1 (es)
NO (1) NO871187L (es)
NZ (1) NZ219717A (es)
PH (1) PH25296A (es)
PT (1) PT84580B (es)
ZA (1) ZA872137B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321655D0 (en) * 1993-10-20 1993-12-08 Glyzinc Pharma Ltd Pharmaceutical formulation of aspirin and salicylates
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
DE10352511A1 (de) * 2003-11-07 2005-06-16 Ernst-Moritz-Arndt-Universität Greifswald Verwendung von MRP4-Inhibitoren zur Behandlung und/oder Prophylaxe kardiovaskulärer Erkrankungen
HU231309B1 (hu) 2014-02-25 2022-11-28 Darholding Kft. Nanostrukturált Indomethacint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás előállításukra

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1029660A (en) * 1973-06-01 1978-04-18 Kyowa Hakko Kogyo Co. Prevention of gastric lesions
AU511852B2 (en) * 1977-11-09 1980-09-11 Australian National University, The Formulating aspirin andthe like
DE2966867D1 (en) * 1979-01-12 1984-05-10 Univ Australian Protection of the gastric mucosal lining from damage by aspirin and related drugs
US4228161A (en) * 1979-03-28 1980-10-14 Merck & Co., Inc. Anti-inflammatory combination having reduced ulcerogenicity
ZA836030B (en) * 1983-08-16 1985-02-27 Verex Lab Constant order release solid dosage indomethacin formulation and method of treating arthritis and other inflammatory conditions
GB2155329A (en) * 1984-03-08 1985-09-25 Kim Drummond Rainsford A pharmaceutical formulation containing azapropazone
DE3580140D1 (de) * 1984-03-14 1990-11-22 Jerome Corbiere Verfahren zum loesen von wirksubstanzen und auf diese weise erhaltene arzneimittel.
ATE86110T1 (de) * 1984-12-20 1993-03-15 Sandoz Ag Behandlung von gastrointestinalkrankheiten durch anwendung von 5-ht3-antagonisten.

Also Published As

Publication number Publication date
GB8607662D0 (en) 1986-04-30
US4885279A (en) 1989-12-05
DK154887D0 (da) 1987-03-26
AU7071387A (en) 1987-10-01
IE870742L (en) 1987-09-27
NZ219717A (en) 1989-06-28
PT84580B (pt) 1989-11-30
NO871187D0 (no) 1987-03-23
JPS6322017A (ja) 1988-01-29
NO871187L (no) 1987-09-28
PH25296A (en) 1991-04-30
IE59636B1 (en) 1994-03-09
EP0239332B1 (en) 1991-02-27
AU593084B2 (en) 1990-02-01
DK154887A (da) 1987-09-28
DE3768110D1 (de) 1991-04-04
ZA872137B (en) 1987-10-28
JPH0572887B2 (es) 1993-10-13
EP0239332A2 (en) 1987-09-30
GR3001520T3 (en) 1992-11-23
CA1285488C (en) 1991-07-02
PT84580A (en) 1987-04-01
EP0239332A3 (en) 1988-03-02
ATE60993T1 (de) 1991-03-15

Similar Documents

Publication Publication Date Title
NO922232L (no) Fysiologisk aktive, polypeptid-holdige, farmasoeytiske preparater
ATE87471T1 (de) Eine fluessige verabreichungsform fuer orale verabreichung einer pharmazeutischen substanz.
MY102459A (en) Oral sustained release pharmaceutical preparation.
AU528190B2 (en) Device for oral administration of drugs to ruminant animals
NO174412C (no) Fremgangsmåte for fremstilling av en farmasöytisk formulering med programmert frigjöring for oral anvendelse
NO864425D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocyklyloksoftalazinyl-eddiksyre-derivater.
ES2048594T3 (es) Formulaciones farmaceuticas.
NO865204L (no) Fremgangsmaate for fremstilling av terapeutisk aktive benzosyre- og benzosyreester-derivater.
ES2038658T3 (es) Una formulacion farmaceutica conteniendo indometacina.
BG60101B2 (bg) Метод за получаване на 4-флуор-2-(((4-метокси-2- пиридинил)метил)тионил)-1н-бензимидазол
IT1131822B (it) Anilidi di acidi (3-alchilamminio-2-idrossipropossi)-furan-2-carbossilici e loro sali di addizione con acidi compatibili dal punto di vista fisiologico e procedimento per la loro preparazione e anche prodotti medicinali che contengono questi composti
ATE165239T1 (de) Orale arzeimittelzubereitung enthaltend diclofenac-natrium und eine organische säure
NO168825C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 3-pyrrolidinyltio-1-azabicyklo (3.2.0) hept-2-en-2-karboksylsyrederivater
DE3265827D1 (en) Pharmaceutical composition of phosphonomicin in tablet form
NO863005D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,4,5,6,7,8-heksahydro-2-alkyl-4-aryl-5-okso-1,7-naftyridin-3-karboksylsyreesterderivater.
RU94001686A (ru) Иммуномодулирующее лекарственное средство
JPS57112329A (en) Drug against arterioschlerosis comprising 2,3- dihydroxypropyl ester of n-(7-chloro-4-quinolyl) anthranillic acid
SE8800888L (sv) Foerfarande foer framstaellning av ett laekemedelspreparat foer foerebyggande och behandling av alkoholism

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 239332

Country of ref document: ES